Care Guideline	Minimum Frequency	RESP
DIABET	ES E08,E09,E10,E11,E13	
WELLNESS	YEARLY	Reception
FOLLOW UP OFFICE VISIT	6 months(if HgbA1c>=7.0 Q3months)	Reception
Pneumonia Vaccine	See Recommendation in Women/Mens Health	Clinical
LABS		
	6 months at least twice annually(if HgbA1c >=7.0 Q3 Months to	
HgA1C	Age <75)	LAB
Fasting Lipid panel-**stop standing orders at		
age 85	YEARLY (if LDL> 100 follow IVD guidelines)	REC(LAB)
BMP	Q3month	Reception
Micro albumin	YEARLY	Reception
	1. Administer the Hepatitis B Vaccine series to all unvaccinated	
	patients with Diabetes ages 18-59 years old 2. For patients 60 years or older, assess their risk for developing	
	Hepatitis B, considering their likelihood to respond to	
	vaccinations, and if they are in a long term care facility (higher	
	risk) 3. If	
	unable to determine vaccination status: Patient born in 1980 or	
Hepatitis B Vaccine / Titers	earlier, order titers, if born after 1980 consider titers.	PCP
•	Statin therapy recommended for Age >40 with Diabetes more	
	than 10 years. Use risk calculator to determine high dose vs	
STATIN MED	moderated dose	PCP
EYE EXAM	YEARLY	Reception
REFERRALS		
DM Education/Nutrition	Initial Diagnosis, and If HgbA1c>8.0	PCP
	TING GLUCOSE/PRE-DIABETES All R73	
WELLNESS	YEARLY	Reception
LABS		
Fasting Glucose, HgbA1c	YEARLY	LAB
	VASCULAR DISEASE I20-25,I70-72	
WELLNESS	YEARLY	Reception
FOLLOW UP OFFICE VISIT	6 months(if Low dose meds and LDL>100 Q3 months)	Reception
LABS- **stop standing orders at age 85		
Lipid panel- on high dose meds	YEARLY	REC(LAB)
Lipid panel- on low dose meds	YEARLY, if LDL>100 Q6months	REC(LAB)
Fasting Glucose	with all lipid panels	LAB
	HEART FAILURE 111,142,143,150	
WELLNESS	YEARLY	Reception
FOLLOW UP OFFICE VISIT	6 months (if BP >=130/80 q3months)	Rec/Prov
Ejection Fraction Measurement	Documented in Chart	Provider
Diuretic titration per protocol	See protocol	CM/ Nsg
LABS	·	
Basic Metabolic Panel	Q3 months	LAB
CMP	YEARLY (replaces one interval of BMP)	LAB
ANTICOAGULA	ATION (includes NOAC patients)	
WELLNESS	YEARLY	Reception
FOLLOW UP OFFICE VISIT	6 months	Reception
LABS		
Basic Metabolic Panel, CBC	YEARLY	LAB
,		

Care Guideline	Minimum Frequency	RESP
НҮГ	PERTENSION 110-115	
WELLNESS	YEARLY	Reception
FOLLOW UP OFFICE VISIT	6 months (if BP >= 130/80 Q3 months)	Reception
EKG	At initial diagnosis visit	Provider
LABS		
Basic Metabolic Panel	Q3 months	LAB
Lipid panel**stop standing orders at age 85	YEARLY	LAB
HYP	ERLIPIDEMIA AII E78	
WELLNESS OR FOLLOW UP	YEARLY	Reception
LABS- **stop standing orders at age 85		
Lipid Panel	YEARLY	Reception
Fasting Glucose	YEARLY	LAB
	DEPENDENCE Z72.0,Z87.891	
WELLNESS	YEARLY	Reception
Tobacco use screening	at every visit	Clinical
Cessation counseling (if + screen for use)	at every visit	Provider
Pneumonia Vaccine	See Recommendation in Women/Mens Health	Provider
COPD screening	YEARLY	Clinical
LDCT referral	YEARLY (age 50-80 with 20-pack yr smoking hx)	Provider
	HMA J45.3,J45.4,J45.5	1 TOVIGO
WELLNESS	YEARLY	Reception
FOLLOW UP OFFICE VISIT	6 months	Reception
Pneumonia Vaccine	See Recommendation in Woman/Mens Health	Provider
O2 SATS	at every visit	Clinical
Asthma Control Test (ACT)	Every Asthma Visit	Clinical
	PD J41,J43,J42,J44	Omnoar
WELLNESS	YEARLY	Reception
FOLLOW UP OFFICE VISIT	6 months	Reception
Pulmnary Function Test	At diagnosis	Provider
Pneumonia Vaccine	See Recommendation in Woman/Mens Health	Provider
O2 SATS	at every visit	Clinical
Smoking Cessation (if tobacco user)	at every visit	Provider
,	OTHYROIDISM E03.9	1 Tovidei
WELLNESS	YEARLY	Reception
TSH	YEARLY	LAB
_	PEUTIC DRUG LEVELS	LAD
WELLNESS	YEARLY	Reception
FOLLOW UP OFFICE VISIT	6 months	Reception
Therapeutic Drug Lithium, Digoxin,	6 months (Lithium Q3months)	rteception
Phenobarbital, Valproic, Depkote, anti-seizure	o montris (Ettiliam Qomontris)	
medications, Theophyllin		LAB
BMP, TSH	6 months	LAB
	CSRP	
WELLNESS	YEARLY	Reception
FOLLOW UP OFFICE VISIT AND LABS	Opiates Q3 months/Stimulants Q6 months	Reception
UDS (Opiates)	2X/Year	Clinical
Care Guideline	Minimum Frequency	RESP

СК	D 3 (N18.31/N18.32)	
WELLNESS	YEARLY	Reception
Labs		
Renal Panel	Q6 months	LAB
Urinalysis	YEARLY	LAB
CKI	D 4/5 (N18.4/N18.5)	
WELLNESS	YEARLY	Reception
Labs		•
Renal Panel, PTH, CBC, 25 Hydrox Vit D Phos	Q3 months	LAB
Urinalysis	YEARLY	LAB
	BMI >40 (Z68.41)	
Labs (fasting)	VEADIN	LAD
Lipid Panel, CMP	YEARLY	LAB
	75.8) /Nonalcoholic Fatty Liver Disease (NAFLD)(K76.0)	
Labs		
CMP	YEARLY	LAB
Os	teoporosis (M81.0)	
Labs		
Renal Panel, Vit D	YEARLY	LAB
	parathyoidism (E21.3)	
Labs		
Renal Panel, Vit D, PTH	Q6 months	LAB
1. (a)	GOUT (M10.9)	
Labs		
	OC magnethe	LAB
Uric Acid, BMP	Q6 months	LAD
	K70.3, K74.4 K74.5 K83.01)	
Labs		
CMP, CBC, Protime	Q6 months	LAB
Care Guideline	Minimum Fraguesou	RESP
	Minimum Frequency	RESP
Assigned Female at B	irth Reproductive and Preventive Care	

WELLNESS	Annual to age 25, then Every 2 years Ages 26-65; Then annual	Reception
	>64.	
	Screen once in lifetime, or anyone at high risk	
HIV Screening (Z.202)	Positive Screen Consider Prep	Provider
Syphillis Screening (Z.202)	Anyone at high risk	Provider
Hepatitis C screening	sceen once in lifetime age 18-79, or anyone at high risk	Lab
(Z11.59) (Z.202)		
GC/Chlamydia Screening (Z.202)	Annually all women age 15-24 Begin Screening at age 21. Age 21-30 Q3YEARS. Age 30-65	Clinical
	PAP and HPV co testing Q5yrs. If high risk follow ASCCP	
Cervical Cancer Screening	guidelines	Clinical
Breast Cancer Screening	Q 2 YEARS age 40 to 75. Annual for high risk women.	Reception
Colorectal Cancer Screening	Age 45-75 Colonoscopy Q10 years or 1 FOBT YEARLY	Provider
Baseline Bone Density Screening	Age 65, earlier if risk factors present	Reception
F/U Bone Density Screening	Based on recommendation from previous screening	Reception
EYE EXAM	EVERY 2 YEARS	Reception
Lipid screening	starting at age 40 with risk assessment (family history, lifestyle,	Provider
, , , , , ,	and risk calculator such as AHA 10 yr risk estimate) and at least	
	1	
	every 5 yrs Immunize up to age 18;	Clinical
HPV Vaccine	Refer to pharmacy for ages 18-45	Pharmacy
Pneumonia Vaccine	PCV15 or PCV20 for all adults 65 yrs or older who have never	Pharmacy
i noumonia vaccino	received pneumoccal conjugate vaccine or whose vaccination	linamacy
	history is unknown.	
	PCV15 or PCV20 for adults Age 19-64 with certain chronic	
	conditions.	
	Should be administered at least one year from previous PPSV23	
	dose. If PCV15 is used, this should be followed by one dose of	
	PPSV23 one year later if they have never recieved it. The	
	minumum interval is 8 weeks, and can be used in adults with	
	immunocompromising condition, Cochlear implants or cerebralspinal fluid leak. If PCV20 is used a dose of PPSV23 is	
	not indicated.	
	Adacel (appropriate for age 19-64), or Boostrix (appropriate for	
Tdap Vaccine	age >= 10 y.o) One booster after age 19, Td q10 years.	Clinical
Shingrix	Start at age 50, series of 2 immunizations	Pharmacy
FLU SHOT	YEARLY	Clinical
	th Reproductive and Preventive Care	
WELLNESS	Annual to age 25, then Every 2 years Ages 26-66; Then annual	Reception
	>65.	
Colorectal Cancer Screening	Age 45-75 Colonoscopy Q10 years or 1 FOBT YEARLY	Provider
AAA Screening	ONCE between Age 65-75 with smoking hx 100 or > cigarettes,	Provider
	or +Family HX	
110/ 0 (7.000)	Screen once in lifetime, or anyone at high risk	
HIV Screening (Z.202)	Positive Screen Consider Prep	Provider
Syphillis Screening (Z.202)	Anyone at high risk	Provider
Hepatitis C screening	sceen once in lifetime age 18-79, or anyone at high risk	Lab
(Z11.59) (Z.202) GC/Chlamydia Screening (Z.202)	Annual, anyone who has male to male sex	Provider
GC/Chlamydia Screening (2.202) GC/Chlamydia Screening Anal/Pharyngeal	Annual, anyone with high risk activities	Provider
Anal Pap Smear	At first HIV Diagnosis	Provider
Care Guideline	_	RESP
Care Guideline	Minimum Frequency (AMAB Care Continued)	INESP
EYE EXAM	EVERY 2 YEARS	Reception
Shingrix	Start at age 50, series of 2 immunizations	Pharmacy
Jilligila	Otart at ago 50, series of 2 infilituilizations	ј. паппасу

FLU SHOT	YEARLY	Clinical
Lipid screening	starting at age 40 with risk assessment (family history, lifestyle,	Provider
	and risk calculator such as AHA 10 yr risk estimate) and at least	
	every 5 yrs	
HPV Vaccine	Immunize up to age 18;	Clinical
	Refer to pharmacy for ages 18-45	Pharmacy
	PCV15 or PCV20 for all adults 65 yrs or older who have never	
	received pneumoccal conjugate vaccine or whose vaccination	
	history is unknown.	
	PCV15 or PCV20 for adults Age 19-64 with certain chronic conditions.	
	Should be administered at least one year from previous PPSV23	
	dose. If PCV15 is used, this should be followed by one dose of	
	PPSV23 one year later if they have never recieved it. The	
	minumum interval is 8 weeks, and can be used in adults with	
	immunocompromising condition, Cochlear implants or	
Duovino vio Voccino	cerebralspinal fluid leak. If PCV20 is used a dose of PPSV23 is	
Pneumonia Vaccine	not indicated.	Clinical
Tdap Vaccine	Adacel (appropriate for age 19-64), or Boostrix (appropriate for age >= 10 y.o) One booster after age 19, Td q10 years.	Climinal
Tuap vaccine	Children's Health	Clinical
WELLNESS and Postpartum screen	Children's Health	
(for Mom)	A go Owoolea	Docention
(IOI MOIII)	Age 2weeks	Reception
	Age 4weeks	Reception
WELLNESS	Age 2 months	Reception
WELLINESS	Age 4 months	Reception
	Age 6 months	Reception
	Age 9 months	Reception
	Age 12 months	Reception
	Age 15 months	Reception
	Age 18 months	Reception
	Age 24 months	Reception
BELLAV//OB AL LIE	AGE 3-25 YEARLY	Reception
BEHAVIORAL HEALTH SCREENING	EVERY PHYSICAL VISIT	Clinical
EYE EXAM	AGE 5-25 YEARLY	Reception
FLU SHOT	YEARLY	Clinical
LIPID SCREENING	Consider screening for high risk children	Provider
	Week at a street to a street at the street a	
<u> </u>	gy/Lab standing orders as a result of these guidelines for patients who meet these guidelines annually	
<u> </u>		
Signature	Date	
New Albania (D. 11		
Printed Name of Provider:		